Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway

International Journal of Oncology

Volumn 41, Issue 5, 2012, Pages 1635-1642

  Jiang, Wen G ^a   Ye, Lin ^a   Ji, Ke ^a   Frewer, Natasha ^a   Ji, Jiafu ^a,b   Mason, Malcolm D ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Angiogenesis; Cellular migration; Electric cell substrate impedance sensing; Endothelial cells; Focal adhesion kinase; Tubule forming; Yangzheng Xiaoji

Indexed keywords

ANTINEOPLASTIC AGENT; CHINESE DRUG; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; PF 557328; UNCLASSIFIED DRUG; YANGZHENG XIAOJI; ANGIOGENESIS INHIBITOR; HERBACEOUS AGENT; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CHINESE MEDICINE; COLORIMETRY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SCREENING; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; WESTERN BLOTTING; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84875277907     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1627     Document Type: Article

References (41)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
2. Fidler IJ: Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol (Suppl 43): S3-S10, 1999.
3. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
4. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275: 150-151, 1996
5. Bicknell R and Harris AL: Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8: 60-65, 1996. (Pubitemid 26093744)
6. O'Reilly MS, Homgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994. (Pubitemid 24324921)
7. Harris AL: Clinical trials of anti-vascular agent group B streptococcus toxin (CM101). Angiogenesis 1: 36-37, 1997.
8. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M and Kimura S: Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res 58: 3751-3756, 1998. (Pubitemid 28376579)
9. Gregory RE and DeLisa AF: Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 12: 401-415, 1993. (Pubitemid 23149973)
10. Zhang SY, Gu CH, Gao XD and Wu YL: A random, double-blinded and multicentre study of chemotherapy assisted Yangzhengxiaoji capsule on treating primary hepatic carcinoma. Chin J Diffic Compl Case 8: 461-464, 2009.
11. Wang QL, Xuo CM, Wu XP, Li YX and Bi XJ: Treatment of atypical gastric dysplasia using Yangzheng Xiaoji. Chin J Diffic Compl Case 7: 38-39, 2009.
12. Tran HT, Blumenschein GR Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M and Herbst RS: Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54: 308-314, 2004. (Pubitemid 39304425)
13. Naganuma Y, Choijamts B, Shirota K, Nakajima K, Ogata S, Miyamoto S, Kawarabayashi T and Emoto M: Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci 102: 1545-1552, 2011.
14. Van Wijngaarden J, Snoeks TJ, van Beek E, Bloys H, Kaijzel EL, van Hinsbergh VW and Löwik CW: An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. Biochem Biophys Res Commun 391: 1161-1165, 2010.
15. Woerdenbag HJ, Moskal TA, Pras N, Malingré TM, el-Feraly FS, Kampinga HH and Konings AW: Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod 56: 849-856, 1993. (Pubitemid 23195612)
16. Liu WM, Gravett AM and Dalgleish AG: The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int J Cancer 128: 1471-1480, 2011.
17. Ye Li, Ji K, Ji JF and Jiang WG: Application of electric cell-substrate impedance sensing in evaluation of traditional medicine on the cellular functions of gastric and colorecctal cancer cells. Cancer Metastasis Biol Treat 17: 2012. doi: 10.1007/978-94-007-4927-6-13.
18. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Scott C and Puntis MCA: Inhibition of invasion and motility of human colon cancer cells by gamma linolenic acid. Br J Cancer 71: 744-752, 1995.
19. Giaever I and Keese CR: Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci USA 88: 7896-7900, 1991. (Pubitemid 21915262)
20. Keese CR, Wegener J, Walker SR and Giaever I: Electrical wound-healing assay for cells in vitro. Proc Natl Acad Sci USA 101: 1554-1559, 2004. (Pubitemid 38234193)
21. Jiang WG, Ablin RJ, Kynaston HG and Mason MD: The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvasc Res 77: 150-157, 2009.
22. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L and Mansel RE: Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 7: 71, 2008.
23. Jiang WG, Hiscox SE, Parr C, Martin TA, Matsumoto K, Nakamura T and Mansel RE: Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 5: 3695-3703, 1999.
24. Sanders AJ, Ye L, Mason MD and Jiang WG: The impact of EPLINα (epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis. Angiogenesis 13: 317-326, 2010.
25. Ye L, Martin TA, Parr C, Harrison GM, Mansel RE and Jiang WG: Biphasic effects of 17-beta-estradiol on expression of occludin and transendothelial resistance and paracellular permeability in human vascular endothelial cells. J Cell Physiol 196: 362-369, 2003. (Pubitemid 36775884)
26. Sanders AJ, Parr C, Martin TA, Lane J, Mason MD and Jiang WG: Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. J Cell Physiol 216: 780-789, 2008.
27. Matsuda S, Fujita T, Kajiya M, Takeda K, Shiba H, Kawaguchi H and Kurihara H: Brain-derived neurotrophic factor induces migration of endothelial cells through a TrkB-ERK-integrin αVβ3-FAK cascade. J Cell Physiol 227: 2123-2129, 2012.
28. Gilmore AP and Romer LH: Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell 7: 1209-1224, 1996. (Pubitemid 26260738)
29. Cai J, Parr C, Watkins G, Jiang WG and Boulton M: Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 12: 3510-3517, 2006.
30. Braren R, Hu H, Kim YH, Beggs HE, Reichardt LF and Wang R: Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation. J Cell Biol 172: 151-162, 2006. (Pubitemid 43042637)
31. Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M and Hodivala-Dilke KM: Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med 2: 516-528, 2010.
32. Peng X, Ueda H, Zhou H, Stokol T, Shen TL, Alcaraz A, Nagy T, Vassalli JD and Guan JL: Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovasc Res 64: 421-430, 2004. (Pubitemid 39505421)
33. Li S, Butler P, Wang Y, Hu Y, Han DC, Usami S, Guan JL and Chien S: The role of the dynamics of focal adhesion kinase in the mechanotaxis of endothelial cells. Proc Natl Acad Sci USA 99: 3546-3551, 2002. (Pubitemid 34252144)
34. Lechertier T and Hodivala-Dilke K: Focal adhesion kinase and tumour angiogenesis. J Pathol 226: 404-412, 2012.
35. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G and Sood AK: Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67: 10976-10983, 2007. (Pubitemid 350145927)
36. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA and Siu LL: Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 30: 1527-1533, 2012.
37. Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, Lowrey B, Thomas KS, Bouton AH, Hwang RF, Stelow EB, Parsons JT and Bauer TW: Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther 10: 2135-2145, 2011.
38. Cabrita MA, Jones LM, Quizi JL, Sabourin LA, McKay BC and Addison C: Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol 5: 517-526, 2011.
39. Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, Wang SC, Wu KW, Balraj G, Chang TT, Li WS, Cheng HC and Wang YC: A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 71: 473-483, 2011.
40. Jeon J, Lee J, Kim C, An Y and Choi C: Aqueous extract of the medicinal plant Patrinia villosa Juss. induces angiogenesis via activation of focal adhesion kinase. Microvasc Res 80: 303-309, 2010.
41. Chung BH, Cho YL, Kim JD, Jo HS, Won MH, Lee H, Ha KS, Kwon YG and Kim YM: Promotion of direct angiogenesis in vitro and in vivo by Puerariae flos extract via activation of MEK/ERK-, PI3K/Akt/eNOS-, and Src/FAK-dependent pathways. Phytother Res 24: 934-940, 2010.